MX2007010593A - Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral. - Google Patents

Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.

Info

Publication number
MX2007010593A
MX2007010593A MX2007010593A MX2007010593A MX2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A MX 2007010593 A MX2007010593 A MX 2007010593A
Authority
MX
Mexico
Prior art keywords
synthesis
antiandrogens
pharmacokinetics
novel
biological activities
Prior art date
Application number
MX2007010593A
Other languages
English (en)
Spanish (es)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2007010593A publication Critical patent/MX2007010593A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007010593A 2005-03-02 2006-03-02 Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral. MX2007010593A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
PCT/US2006/007143 WO2006093993A1 (en) 2005-03-02 2006-03-02 Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Publications (1)

Publication Number Publication Date
MX2007010593A true MX2007010593A (es) 2008-02-20

Family

ID=36941503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010593A MX2007010593A (es) 2005-03-02 2006-03-02 Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.

Country Status (21)

Country Link
US (1) US7875599B2 (https=)
EP (2) EP2206719B1 (https=)
JP (2) JP5130453B2 (https=)
KR (1) KR101380959B1 (https=)
CN (2) CN103349664A (https=)
AT (1) ATE482969T1 (https=)
AU (1) AU2006218711B2 (https=)
BR (1) BRPI0607523A2 (https=)
CA (1) CA2599953C (https=)
DE (1) DE602006017175D1 (https=)
DK (2) DK1853619T3 (https=)
EA (1) EA019560B1 (https=)
ES (2) ES2528055T3 (https=)
IL (3) IL185608A (https=)
MX (1) MX2007010593A (https=)
NZ (1) NZ561571A (https=)
PL (2) PL1853619T3 (https=)
PT (2) PT2206719E (https=)
SI (2) SI1853619T1 (https=)
WO (1) WO2006093993A1 (https=)
ZA (1) ZA200708106B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
US7875599B2 (en) * 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
EP2167090A4 (en) 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
EP2362872A4 (en) * 2008-10-28 2012-05-30 Biomarin Pharm Inc DECAHYDRO-1H-INDENOCHINOLINONE AND DECAHYDRO-3H-CYCLOPENTAPHENANTHRIDINONE CYP17 HEMMER
GB2479337A (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010091303A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel steroidal cyp17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
EP2506855A4 (en) * 2009-11-30 2014-07-30 Harbor Biosciences Inc ANTICARCINOMA COMPOUNDS AND SCREENING METHODS
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
AU2011343637A1 (en) * 2010-12-16 2013-05-30 Biomarin Pharmaceutical Inc. C- 17 -heteroaryl steroidal compounds as inhibitors of CYP11B, CYP17, and/or CYP21
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US9694005B2 (en) 2013-04-04 2017-07-04 University Of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
SG11201605178WA (en) 2013-12-24 2016-07-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
US11390645B2 (en) 2016-08-08 2022-07-19 Industriale Chimica S.R.L. Process for the preparation of 3β-hydroxy-17-(1H-benzimidazol-1-YL) androsta-5,16-diene
CA3087286C (en) 2018-02-13 2023-06-27 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
US20200369715A1 (en) * 2018-02-13 2020-11-26 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (https=) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
JP4855253B2 (ja) 2003-07-29 2012-01-18 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 幹細胞動員に有用な医薬の組み合わせ
US7875599B2 (en) * 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity

Also Published As

Publication number Publication date
EP2206719B1 (en) 2014-10-22
ES2528055T3 (es) 2015-02-03
DK1853619T3 (da) 2011-01-10
KR20070120119A (ko) 2007-12-21
SI2206719T1 (sl) 2015-03-31
AU2006218711A2 (en) 2006-09-08
IL210478A0 (en) 2011-03-31
JP5130453B2 (ja) 2013-01-30
PT1853619E (pt) 2011-01-03
CA2599953A1 (en) 2006-09-08
WO2006093993A1 (en) 2006-09-08
EP1853619A4 (en) 2009-08-26
JP2012255026A (ja) 2012-12-27
DE602006017175D1 (de) 2010-11-11
IL210480A0 (en) 2011-03-31
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
PT2206719E (pt) 2015-02-05
NZ561571A (en) 2009-09-25
EA200701872A1 (ru) 2008-06-30
ZA200708106B (en) 2008-12-31
AU2006218711B2 (en) 2010-11-11
AU2006218711A1 (en) 2006-09-08
BRPI0607523A2 (pt) 2009-09-08
PL1853619T3 (pl) 2011-03-31
IL210480A (en) 2015-06-30
US20080280864A1 (en) 2008-11-13
PL2206719T3 (pl) 2015-03-31
CN103349664A (zh) 2013-10-16
KR101380959B1 (ko) 2014-04-04
CA2599953C (en) 2013-08-13
DK2206719T3 (en) 2015-01-26
SI1853619T1 (sl) 2011-01-31
JP2008536807A (ja) 2008-09-11
CN101155823A (zh) 2008-04-02
IL185608A (en) 2016-06-30
IL185608A0 (en) 2008-01-06
EA019560B1 (ru) 2014-04-30
US7875599B2 (en) 2011-01-25
ATE482969T1 (de) 2010-10-15
EP2206719A3 (en) 2011-01-05
EP2206719A2 (en) 2010-07-14
HK1115387A1 (en) 2008-11-28
EP1853619B1 (en) 2010-09-29
ES2353413T3 (es) 2011-03-01

Similar Documents

Publication Publication Date Title
MX2007010593A (es) Inhibidores de cyp17/antiandrogenos esteroideos de heteroailo de c-17 novedosos: sintesis, actividades biologicas in vitro, farmacocinetica y actividad antitumoral.
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
EA017278B9 (ru) Соединения азаиндазола и способы применения
SG141468A1 (en) Novel curcumin analogues and uses thereof
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
IL183160A0 (en) Indazole-carboxamide compounds
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200616615A (en) Compounds and methods for the treatment of cancer
WO2006052889A3 (en) Quinolinone-carboxamide compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200612925A (en) Prodrug substituted benzoxazoles as estrogenic agents
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
WO2007139778A3 (en) Rhamnose substituents of sl0101 and therapeutic uses thereof
TW200634005A (en) Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs

Legal Events

Date Code Title Description
FG Grant or registration